UCB Gets US FDA Nod for Autoinjector Version of Myasthenia Gravis Drug

05:06 AM EDT, 10/16/2026 (MT Newswires) -- UCB (UCB.BR) received approval from the US Food and Drug Administration for the autoinjector administration option for Zilbrysq in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. The once-daily autoinjector automatically delivers a pre-defined dose to simplify self-administration, the Brussels-listed biopharmaceutical company said Friday. Zilbrysq, or zilucoplan, was previously available as a self-administered prefilled syringe. UCB expects the autoinjector to be available in the first quarter of 2027.